At IBDENC, we believe in engage, educate and empower. Our IBD Journal Scan is one way we deliver on that promise: by curating key articles from high-impact journals every month, we offer a clear, expert-driven snapshot of what’s new and noteworthy in IBD research. Whether you're a clinician, researcher, or educator, this resource helps you stay on the frontline of cutting-edge science, with older scans archived so you can revisit past insights as well.
IBD Journal Scan
Key articles from high impact journals in last month
JUL-2026
This month’s featured studies highlight important advances in inflammatory bowel disease (IBD) care, spanning disease monitoring, treatment, surveillance, microbiome science, and global epidemiology. Emerging evidence supports intestinal ultrasound (IUS) as a reliable, non-invasive tool for predicting relapse in Crohn’s disease patients in deep remission, reinforcing its growing role in long-term disease monitoring. New phase 3 data demonstrate encouraging early efficacy of guselkumab for patients with perianal fistulizing Crohn’s disease, addressing a major unmet therapeutic need. Research also shows that the complex mucosal landscape in IBD increases the likelihood of missed adenomas during surveillance colonoscopy, emphasizing the potential value of longer withdrawal times and AI-assisted detection. Mechanistic insights into *Faecalibacterium prausnitzii* strengthen the promise of microbiome-based therapies, while global projections to 2050 underscore the continuing rise in IBD burden, highlighting the need for stronger healthcare systems and expanded access to specialized care worldwide.
Intestinal Ultrasound Predicts Relapse in Crohn's Disease Patients in Deep Remission
A multicenter prospective observational study followed Crohn's disease patients who had achieved deep remission over 18 months to determine whether intestinal ultrasound parameters could predict subsequent clinical relapse. The study was motivated by the fact that although endoscopy remains central to CD monitoring, its invasiveness and bowel-preparation requirements limit its use for continuous surveillance, whereas transabdominal ultrasound offers a non-invasive, radiation-free, low-cost alternative better suited to long-term follow-up. Patients were stratified by Montreal classification, and color Doppler ultrasound parameters were compared between those who relapsed and those who remained in remission, with a predictive model subsequently developed. For clinicians already using IUS in practice, this adds to a growing evidence base supporting its role not just for treatment response assessment but for prognostication in patients who appear clinically quiet.
Guselkumab Shows Early Efficacy for Perianal Fistulizing Crohn's Disease (FUZION Trial)
Perianal fistulizing Crohn's disease remains one of the most difficult phenotypes to treat, and options with robust trial data are limited. The phase 3 FUZION trial, presented at DDW 2026, evaluated guselkumab in patients with at least one active draining perianal fistula, all of whom had failed or were intolerant to corticosteroids, immunosuppressants, or up to two classes of advanced therapy. Patients were randomized in a 2:2:1 ratio to 12 weeks of induction with guselkumab or placebo, followed by extended maintenance dosing at two different guselkumab regimens over a total 96-week treatment period. The 24-week results add to the accumulating guselkumab dataset (following GALAXI 2/3 and long-term extension data) and offer cautious optimism for a historically underserved patient population.
Why Are Adenomas Missed More Often During IBD Surveillance Colonoscopy?
A prospective observational study addressed a practical quality concern: does cognitive load during surveillance colonoscopy explain lower adenoma detection rates (ADR) in IBD patients compared with non-IBD patients undergoing routine screening? Using a video library of colonoscopies performed over three years at a tertiary center, the study compared ADR between 241 IBD and 1,266 non-IBD colonoscopies. When withdrawal time was held constant at 11.7 minutes, ADR in the IBD group was substantially lower than in the non-IBD group (16.5% vs 42.6%). The findings suggest that the visual complexity of inflamed or scarred IBD mucosa genuinely raises the cognitive burden of lesion detection, reinforcing calls for longer withdrawal times — or dedicated AI-assisted detection tools - specifically in IBD surveillance.
How Does Faecalibacterium prausnitzii Actually Reduce Gut Inflammation?
While the live biotherapeutic EXL01 (derived from F. prausnitzii) has already generated excitement following its first-in-human safety trial in Crohn's disease, a complementary mechanistic study in this journal digs into how this organism produces its anti-inflammatory effect. The bacterium has previously been shown to have anti-inflammatory properties in human and mouse models, largely through induction of IL-10 signaling, and this study set out to identify which specific human cell types are responsible for producing IL-10 in response to F. prausnitzii exposure. By characterizing the precise immune cell populations and signaling pathways involved, the work strengthens the biological rationale for F. prausnitzii-based live biotherapeutics and may help identify which patients are most likely to respond to this emerging drug class.
The Global Burden of IBD Across G20 Nations: Projections to 2050
A systematic analysis using Global Burden of Disease 2021 data examined IBD trends across G20 countries from 1990 to 2021, with projections extending to 2050. Between 1990 and 2021, age-standardized rates for prevalence and mortality actually declined slightly across G20 nations, while incidence and disability-adjusted life years (DALYs) rose — and absolute case numbers and deaths nearly doubled over the period. Notably, the burden differed by sex: women had higher prevalence and disability burden, while men had higher incidence and mortality, and Canada and Germany recorded the highest DALY rates. For an ENC audience spanning multiple emerging economies, this kind of cross-national projection is a useful reminder that rising incidence — even where prevalence growth appears to be slowing in some high-income settings — will continue to strain healthcare systems still building out IBD care infrastructure.
